Global Musculoskeletal Diseases Treatment Market - 2025-2033

Musculoskeletal Diseases Treatment Market Size

Musculoskeletal Diseases Treatment Market Size reached US$ 176.98 Billion in 2024 and is expected to reach US$ 301.35 Billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033.

Musculoskeletal Diseases Treatment Market The musculoskeletal diseases treatment market is a rapidly evolving sector of the global healthcare industry, addressing a wide spectrum of disorders that affect the body's bones, muscles, joints, ligaments, and tendons. These conditions are a leading cause of disability worldwide, significantly impacting quality of life, work productivity, and healthcare expenditures. The increasing prevalence of chronic musculoskeletal conditions, such as osteoarthritis, rheumatoid arthritis, osteoporosis, and lower back pain, is driving substantial demand for effective treatment solutions ranging from pharmacological therapies to surgical interventions and regenerative medicine.

Musculoskeletal Diseases Treatment Market Dynamics: Drivers & Restraints

The rising prevalence of musculoskeletal diseases is significantly driving the market growth

As populations age, degenerative conditions like osteoarthritis become more prevalent. According to the World Health Organization, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female, a number projected to rise sharply by 2030. This surge has driven demand for NSAIDs, joint replacement surgeries, and biologic treatments such as adalimumab and etanercept. Autoimmune-related musculoskeletal diseases such as rheumatoid arthritis and ankylosing spondylitis are increasing globally. This has led to higher utilization of disease-modifying antirheumatic drugs (DMARDs) and biologic therapies, boosting sales for companies like AbbVie (Humira) and Amgen (Enbrel).

Taken together, the sheer growth in musculoskeletal disease prevalence across osteoarthritis, rheumatoid arthritis, low back pain, and beyond creates an ever-larger pool of patients requiring lifelong management, complex surgeries, and emerging regenerative therapies. Each incremental increase in case numbers ripples through the treatment continuum, expanding volumes of drugs dispensed, procedures performed, and rehabilitative services delivered and thereby underpinning the sustained, double-digit growth rates enjoyed by the musculoskeletal diseases treatment market.

Low patient adherence to long-term therapies is hampering the musculoskeletal diseases treatment market

Musculoskeletal conditions like rheumatoid arthritis, osteoarthritis, and chronic back pain require long-term and often lifelong management through medications, physiotherapy, and lifestyle changes. However, many patients discontinue treatment prematurely due to a lack of immediate symptom relief (especially with DMARDs or physical therapy), side effects from medications (e.g., GI issues from NSAIDs or nausea from methotrexate), and the perception that the condition is ""manageable"" without continued therapy.

Biologic therapies such as TNF inhibitors like adalimumab require regular injections or infusions. Adherence rates for biologics are often below 60% after 12 months, especially in self-administered formats, reducing the potential for recurring revenue. For instance, poor compliance with biologic therapy in ankylosing spondylitis can lead to disease flare-ups and surgical complications, but more critically for the market, it decreases the lifetime value of each patient for pharma companies.

Musculoskeletal Diseases Treatment Market Segment Analysis

The global musculoskeletal diseases treatment market is segmented based on disease type, treatment type, and region.

The arthritis from the disease type segment is expected to hold 21.65% of the market share in 2024 in the musculoskeletal diseases treatment market

Arthritis, including osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, and gout, affects over 350 million people globally, and numbers are rising due to aging populations, obesity, and sedentary lifestyles. For instance, in the U.S. alone, 1 in 4 adults (∼54 million people) have been diagnosed with arthritis. That number is expected to exceed 78 million by 2040, according to the Centers for Disease Control and Prevention. This creates a large, chronic demand for long-term treatment options.

A significant portion of R&D investment in the musculoskeletal diseases treatment market is directed toward arthritis therapies, with the development of various therapies by market players. For instance, in January 2025, Celltrion announced that the U.S. Food and Drug Administration (FDA) approved AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA. AVTOZMA is indicated for the treatment of multiple diseases, including rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and systemic juvenile idiopathic arthritis (sJIA).

Additionally, In April 2025, Cytonics, an early-stage biopharmaceutical company developing therapies for osteoarthritis, announced that the last patient has completed their last visit in the Company's first-in-human clinical trial of CYT-108, a novel recombinant protein variant of an endogenous, broad-spectrum protease inhibitor, delivered twice (90 days apart) via intra-articular injection into arthritic knees.

Musculoskeletal Diseases Treatment Market Geographical Analysis

North America is expected to dominate the global musculoskeletal diseases treatment market with a 42.12% share in 2024

North America leads in the use of biologics, biosimilars, regenerative medicine (like stem cell therapies), and robotic-assisted surgeries, which are high-revenue segments. For instance, the U.S. accounts for the largest share of global biologic sales, with drugs like Humira (adalimumab, for rheumatoid arthritis) generating over $10 billion in annual revenue in the U.S. alone before biosimilar entry. This rising biosimilar landscape is boosting the market in the region with various biosimilar launches into the musculoskeletal disease treatment market.

For instance, in February 2025, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech have announced the availability of SELARSDI (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara (ustekinumab) for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis.

Moreover, the presence of the major market players in North America, especially in the United States, is developing various therapeutics for the treatment of musculoskeletal diseases, further accelerating the market growth in the region. For instance, in September 2024, UCB announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS). BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Asia-Pacific is growing at the fastest pace in the musculoskeletal diseases treatment market, holding 21.97% of the market share

Pharma and medtech giants are expanding their footprints in Asia-Pacific, especially into Japan, China, and India, through partnerships, local manufacturing, and product launches tailored to regional needs. For instance, in July 2024, LG Chem is making a concerted effort to penetrate the Chinese osteoarthritis treatment market. LG Chem announced that its Chinese partner, Yifan Pharmaceutical, has launched LG Chem’s single-injection osteoarthritis treatment, Synovian, in the Chinese market.

Countries like India, Thailand, and Malaysia have become hubs for affordable orthopedic surgeries and rehab services, attracting patients from across Asia, Africa, and the Middle East. Asia-Pacific is experiencing one of the most significant demographic transitions globally, with a rapidly aging population prone to degenerative musculoskeletal conditions like osteoarthritis and osteoporosis.

Musculoskeletal Diseases Treatment Market Top Companies

Top companies in the musculoskeletal diseases treatment market include Pfizer Inc., Koninklijke Philips N.V., Novartis AG, Abbott, F. Hoffmann-La Roche Ltd, Stryker Corporation, Amgen Inc., Medtronic, Arthrex, Inc., and Globus Medical, among others.

Musculoskeletal Diseases Treatment Market Key Developments

In May 2025, Shares of Biocon Ltd rose as much as 2% after its subsidiary stated that its Japanese commercial partner released the Ustekinumab BS Subcutaneous injection for the treatment of psoriatic arthritis. Ustekinumab BS Subcutaneous injection is a biosimilar version of the reference medicine Stelara (Ustekinumab).

In March 2025, FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if intravenous infusion affects signs and symptoms of oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) and improve quality of life in suffering children aged 2 – 16 years old.

In May 2025, the Bone Health and Osteoporosis Foundation (BHOF) is stepping into May with a new challenge and a clear goal: to raise awareness about osteoporosis and encourage healthy habits to help prevent broken bones. In recognition of Osteoporosis Awareness and Prevention Month, BHOF is launching the Walk a Mile a Day in May initiative, encouraging people of all ages to take just 2,000 steps a day in support of bone health.

The global musculoskeletal diseases treatment market report delivers a detailed analysis with 50+ key tables, more than 45+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.